Multicountry Spread of Influenza A(H1N1)pdm09 Viruses with Reduced Oseltamivir Inhibition, May 2023-February 2024

Emerg Infect Dis. 2024 Jul;30(7):1410-1415. doi: 10.3201/eid3007.240480.

Abstract

Since May 2023, a novel combination of neuraminidase mutations, I223V + S247N, has been detected in influenza A(H1N1)pdm09 viruses collected in countries spanning 5 continents, mostly in Europe (67/101). The viruses belong to 2 phylogenetically distinct groups and display ≈13-fold reduced inhibition by oseltamivir while retaining normal susceptibility to other antiviral drugs.

Keywords: H1N1; Influenza; United States; antimicrobial resistance; antiviral; baloxavir; influenza A(H1N1)pdm09; neuraminidase inhibitors; oseltamivir; pH1N1; phenotypic testing; reduced inhibition; substitution; viruses.

MeSH terms

  • Antiviral Agents* / pharmacology
  • Antiviral Agents* / therapeutic use
  • Drug Resistance, Viral* / genetics
  • Humans
  • Influenza A Virus, H1N1 Subtype* / drug effects
  • Influenza A Virus, H1N1 Subtype* / genetics
  • Influenza, Human* / drug therapy
  • Influenza, Human* / epidemiology
  • Influenza, Human* / virology
  • Mutation
  • Neuraminidase* / antagonists & inhibitors
  • Neuraminidase* / genetics
  • Oseltamivir* / pharmacology
  • Oseltamivir* / therapeutic use
  • Phylogeny*

Substances

  • Oseltamivir
  • Antiviral Agents
  • Neuraminidase